30 results about "HIV envelope protein" patented technology

The invention relates to an immunogen comprising an HIV envelope protein bound to a ligand, which ligand upregulates at least one of the CD4 binding site and the CCR5 binding site on the protein, and bound to an HR-2 peptide. The invention also relates to a method of inducing anti-HIV antibodies using such an immunogen.

Synthetic HIV envelope proteins, vectors and compositions thereof, and methods for inducing protective immunity against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in vaccines to provide improved protective immunity against HIV.

The present invention provides device and method for fast detection of endogenous antibody, especially HIV envelope protein resisting antibody, in urine. Other pathogens, including known pathogen of sexually transmitted disease, capable of causing the raising of endogenous antibody may be also detected with the device and method of the present invention.

The invention relates to polynucleotides for DNA vaccination which polynucleotides encode an HIV envelope protein or fragment or immunogenic derivative, which is non-glycosylated when expressed in a mammalian target cell, operably linked to a heterologous promoter. Preferably the HIV envelope molecule, such as gp120 or gp140 or gp160, lacks a functional secretion signal. It may be fused to additional HIV proteins such as Nef, Gag, RT or Tat.

The invention relates to the fields of molecular virology and genetic engineering. In particular, the invention relates to an HIV (human immunodeficiency virus) envelope protein, a coding sequence thereof, and an HIV pseudovirus comprising the HIV envelope protein; the HIV pseudovirus can be used to detect ADCC (antibody-dependent cell-mediated cytotoxicity) activity of an anti-HIV antibody. The invention also relates to a kit for detecting the ADCC activity of the anti-HIV antibody. The invention further relates to a method for detecting the ADCC activity of the anti-HIV antibody by using the HIV pseudovirus, the method can achieve rapid, simple and high-throughput detection of the ADCC activity of the anti-HIV antibody, and thereby the method is of great significance for protection effect on analysis of vaccine immune response, and development and quality control of a new vaccine.

A clinic human experiment of HIV envelope protein gp120 or gl160 antigen vaccine proves that it can not prevent the infection of HIV to human body, but can be used to research and screen the anti-HIV therapeutic vaccine and the vaccine for preventing the infection of HIV to human body.

The invention relates to polynucleotides for DNA vaccination which polynucleotides encode an HIV envelope protein or fragment or immunogenic derivative fused to an additional HIV protein selected from a non-structural protein or capsid protein or fragment or immunogenic derivative thereof. Preferably the HIV envelope molecule is gp120 and preferred fusions include one or more of HIV Nef, Gag, RT or Tat. Preferably the HIV envelope molecule is non-glycosylated in mammalian cells.

Human immunodeficiency virus (HIV) envelope proteins having specified mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield. Also provided are particles displaying the HIV envelope proteins, nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, particles, nucleic acid, or vectors.

Described herein is a process for protein purification, particularly a process for the purification of a glycoprotein, such as an HIV envelope protein, useful for vaccines or biotherapeutics.

Pharmaceutical composition for treating/preventing HIV comprising (i) a polynucleotide encoding HIV envelope protein and (ii) a polynucleotide encoding CD4 receptor protein or; (i) a polynucleotide encoding HIV envelope protein and (ii) a CD4 receptor protein or; a fixed cell expressing an HIV envelope protein complexed with a CD4 receptor protein. Also disclosed are pharmaceutical compositions for treating/preventing HIV comprising an antibody immunospecific for a fixed cell expressing an HIV envelope protein complex with a CD4 receptor protein. The binding of the CD4 to the HIV envelope protein, i.e. gp120, exposes hidden epitopes that may be used as targets in immunotherapy; the presentation of the gp120 and CD4 in the present forms is said to overcome problems with prior art soluble gp120-CD4 complexes.

The present invention provides a multispecific anti-HIV antibody that binds to multiple epitopes on HIV envelope protein, wherein the antibody comprises: i. an amino acid sequence that binds to a V1/V2 apex glycan epitope; ii. an amino acid sequence that binds to a V3-base glycan region epitope; iii. an amino acid sequence that binds to a CD4 binding site (CD4bs) epitope; iv. an amino acid sequence that binds to a gp120/gp41 interface epitope; and v. an amino acid sequence that binds to a membrane proximal external region (MPER) epitope.

The invention provides methods and compositions for eliciting broad immune responses to HIV envelope proteins. The methods include use of nucleic acids constructs that encode conserved elements of HIV Env to induce immune responses.

The present invention provides virus-like particles and methods of manufacture and use thereof. In accordance with the instant invention, virus-like particles (VLPs), particularly human immunodeficiency virus (HIV) VLPs, are provided. The HIV VLPs comprise at least one HIV structural protein and the HIV envelope protein, but lacks the HIV genome and lacks functional reverse transcriptase and integrase.

The peptide in this invention is a peptide having affinity to gp120 represented by Formula (1): H-A1-A2-A3-A4-A5-R(SEQ ID No. 1)

• • (in the formula,
    • H means hydrogen,
    • A1 is aspartic acid, lysine, valine, glutamic acid, glycine, asparagine, or tyrosine residue,
    • A2 is valine, aspartic acid, tryptophan, lysine, phenylalanine, isoleucine,
    • leucine, or tyrosine residue,
    • A3 is lysine, valine, aspartic acid, arginine, alanine, or tryptophan residue,
    • A4 is alanine, tryptophan, or glycine residue,
    • A5 is glycine, alanine, valine, leucine, isoleucine, serine, threonine, methionine, asparagine, glutamine, histidine, lysine, arginine, phenylalanine, tryptophan, proline, or tyrosine residue,
    • R is OH derived from carboxyl group or NH₂ derived from acid amide group).

The above peptide has an affinity to gp120 of the HIV envelope protein and is superior in stability.